Alisertib

GSK's linerixibat, an IBAT inhibitor, shows promise for PBC-related itch, achieving significant itch reduction in Phase III. Novartis' TAK-756 targets OA with minimal systemic exposure. Enterprise's ETD001, an ENaC inhibitor, advances in CF treatment. Aligos' ALG-000184 reduces HBV markers, offering CHB treatment potential. Roche's compound 39 improves NLRP3 inhibition. Servier's compound 23 targets KEAP1/Nrf2 axis. Accent's ATX968 inhibits DHX9, targeting MSI-H/dMMR cancers. Gilead's GS-2278, an LPAR1 antagonist, discontinued for IPF due to CNS toxicity. Insilico's compound 13 shows promise in CDK7 inhibition with reduced toxicity. Alisertib, an AURKA inhibitor, explored in cancer trials, shows potential in reversing immunotherapy resistance.

Tempus announces four abstracts accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, highlighting research on molecular profiling, tumor immune microenvironment, and biomarkers for CDK4/6 inhibitor resistance.

Developed a system using the air–liquid interface method to maintain lymphoma tissues ex vivo, preserving viability, proliferation, structure, and cellular composition. Optimized conditions using RGD-hydrogel and BAFF, maintaining B-cell viability and tissue architecture for up to 1 week. Human lymphomoids retained cell heterogeneity and could be used to test sensitivity to different compounds, with results largely matching clinical responses.

The biotech industry is growing rapidly due to advancements in genomic research, personalized medicine, and innovative platforms, with key stocks like HRMY, TRDA, and PBYI leading the charge. The global biotechnology market is projected to reach $4.61 trillion by 2034, driven by increased investment, favorable regulations, and high demand for novel therapies. TRDA specializes in EEV therapeutics for neuromuscular diseases, HRMY focuses on rare and neurological diseases, and PBYI develops cancer treatments, all showing strong financials and growth potential.

Puma Biotechnology granted a 7,500-share restricted stock unit award to a new non-executive employee on Dec 2, 2024, under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with vesting conditions tied to continued employment.

Puma Biotechnology (NASDAQ: PBYI) approved a 7,500-share restricted stock unit award for a new non-executive employee under its 2017 Employment Inducement Incentive Award Plan. The award vests over three years, with one-third vesting on December 1, 2025, and one-sixth every six months thereafter, contingent on continued employment, complying with Nasdaq Listing Rule 5635(c)(4).

A phase 2 study, ALISCATM-Breast1, has begun for HR-positive, HER2-negative metastatic breast cancer patients to evaluate alisertib, an Aurora A kinase inhibitor. The study aims to determine the optimal dose of alisertib plus endocrine therapy, with main goals including objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. Initial data is expected in 2025.

Puma Biotechnology initiates ALISCA™-Breast1 Phase II trial of alisertib combined with endocrine therapy for HR+, HER2-negative recurrent or metastatic breast cancer patients previously treated with CDK 4/6 inhibitors. The trial aims to determine the optimal alisertib dose and evaluate efficacy endpoints within biomarker subgroups, with initial data expected in 2025.